ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

Lumateperone Monotherapy for the Treatment of Bipolar Depression Conducted Globally

ClinicalTrials.gov ID: NCT03249376

Public ClinicalTrials.gov record NCT03249376. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 19, 2026, 9:34 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Assess the Efficacy and Safety of Lumateperone Monotherapy in the Treatment of Patients With Major Depressive Episodes Associated With Bipolar I or Bipolar II Disorder (Bipolar Depression) Conducted Globally

Study identification

NCT ID
NCT03249376
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Intra-Cellular Therapies, Inc.
Industry
Enrollment
381 participants

Conditions and interventions

Interventions

  • Lumateperone Drug
  • Placebo Other

Drug · Other

Eligibility (public fields only)

Age range
18 Years to 75 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Nov 26, 2017
Primary completion
Feb 28, 2019
Completion
Feb 28, 2019
Last update posted
Jun 2, 2022

2017 – 2019

United States locations

U.S. sites
14
U.S. states
11
U.S. cities
14
Facility City State ZIP Site status
Clinical Site Birmingham Alabama 35294
Clinical Site Sherman Oaks California 91403
Clinical Site Miami Florida 33133
Clinical Site Orange City Florida 32763
Clinical Site Atlanta Georgia 30322
Clinical Site Decatur Georgia 30030
Clinical Site Chicago Illinois 60612
Clinical Site Joliet Illinois 60435
Clinical Site Shreveport Louisiana 71101
Clinical Site St Louis Missouri 63128
Clinical Site Buffalo New York 14215
Clinical Site Charlotte North Carolina 28211
Clinical Site The Woodlands Texas 77381
Clinical Site Bothell Washington 98011

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 33 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT03249376, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jun 2, 2022 · Synced May 19, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT03249376 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →